The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells

References

• Yarden Y, Kuang W J, Yang-Feng T, Coussens L, Munemitsu S, Dull T J, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J 1987; 6: 3341–3351
   PubMed Web of Science ®Google Scholar
• Qiu F H, Ray P, Brown K, Barker P E, Jhanwar S, Ruddle F H, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family–oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. Embo J 1988; 7: 1003–1011
   PubMed Web of Science ®Google Scholar
• Zsebo K M, Williams D A, Geissler E N, Broudy V C, Martin F H, Atkins H L, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63: 213–224
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang R, Joachimiak A, Schlessinger J, Kong X P. Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA 2000; 97: 7732–7737
   PubMed Web of Science ®Google Scholar
• Hubbard S R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 464–471
   PubMed Web of Science ®Google Scholar
• Mol C D, Dougan D R, Schneider T R, Skene R J, Kraus M L, Scheibe D N, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279: 31655–31663
   PubMed Web of Science ®Google Scholar
• Orfao A, Garcia-Montero A C, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12–30
   PubMed Web of Science ®Google Scholar
• Simmons P J, Aylett G W, Niutta S, To L B, Juttner C A, Ashman L K. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol 1994; 22: 157–165
   PubMed Web of Science ®Google Scholar
• Metcalfe D D. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 2005; 116: 185–203, discussion 184–203
   PubMedGoogle Scholar
• Huizinga J D, Thuneberg L, Kluppel M, Malysz J, Mikkelsen H B, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347–349
   PubMed Web of Science ®Google Scholar
• Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 1995; 153: 511–515
   PubMed Web of Science ®Google Scholar
• Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991; 51: 2416–2419
   PubMed Web of Science ®Google Scholar
• Bene M C, Bernier M, Casasnovas R O, Castoldi G, Knapp W, Lanza F, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596–599
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–580
   PubMed Web of Science ®Google Scholar
• Andersson J, Sjogren H, Meis-Kindblom J M, Stenman G, Aman P, Kindblom L G. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15–22
   PubMed Web of Science ®Google Scholar
• Emile J F, Theou N, Tabone S, Cortez A, Terrier P, Chaumette M T, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2: 597–605
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless C L, Fletcher J A, McGreevey L, Haley A, Griffith D, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305–313
   PubMed Web of Science ®Google Scholar
• Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004; 58: 62–71
   PubMed Web of Science ®Google Scholar
• Lorenzo F, Nishii K, Monma F, Kuwagata S, Usui E, Shiku H. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leuk Res 2006; 30: 1235–1239
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744–752
   PubMed Web of Science ®Google Scholar
• Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661–663
   PubMed Web of Science ®Google Scholar
• Feger F, Ribadeau A Dumas, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110–114
   PubMed Web of Science ®Google Scholar
• Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114: 61–69
   PubMed Web of Science ®Google Scholar
• Horny H P, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74: 121–132
   PubMed Web of Science ®Google Scholar
• Frohling S, Scholl C, Gilliland D G, Levine R L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285–6295
   PubMed Web of Science ®Google Scholar
• Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736–1744
   PubMed Web of Science ®Google Scholar
• Kanakura Y, Furitsu T, Tsujimura T, Butterfield J H, Ashman L K, Ikeda H, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994; 8: S18–S22
   PubMed Web of Science ®Google Scholar
• Care R S, Valk P J, Goodeve A C, Abu-Duhier F M, Geertsma-Kleinekoort W M, Wilson G A, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003; 121: 775–777
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Stirewalt D L, Alonzo T A, Zhang Q, Sweetser D A, Woods W G, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003; 102: 1474–1479
   PubMed Web of Science ®Google Scholar
• Beghini A, Ripamonti C B, Cairoli R, Cazzaniga G, Colapietro P, Elice F, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004; 89: 920–925
   PubMed Web of Science ®Google Scholar
• Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19: 1361–1366
   PubMed Web of Science ®Google Scholar
• Wang Y Y, Zhou G B, Yin T, Chen B, Shi J Y, Liang W X, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102: 1104–1109
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti C B, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463–3468
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kohl T M, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791–1799
   PubMed Web of Science ®Google Scholar
• Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999; 105: 894–900
   PubMed Web of Science ®Google Scholar
• Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20: 965–970
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert A S, Mrozek K, Chen H, Kittles R A, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911
   PubMed Web of Science ®Google Scholar
• Beghini A, Peterlongo P, Ripamonti C B, Larizza L, Cairoli R, Morra E, et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727
   PubMed Web of Science ®Google Scholar
• Goemans B F, Zwaan C M, Miller M, Zimmermann M, Harlow A, Meshinchi S, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2008; 22: 303–307
   PubMed Web of Science ®Google Scholar
• Shih L Y, Liang D C, Huang C F, Chang Y T, Lai C L, Lin T H, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia, in press
   Web of Science ®Google Scholar
• Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806–1809
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Kilic M, Westhoff M A, Reinhardt D, Fulda S, Debatin K M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006; 108: 3504–3513
   PubMed Web of Science ®Google Scholar
• Nagata H, Worobec A S, Oh C K, Chowdhury B A, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560–10564
   PubMed Web of Science ®Google Scholar
• Longley B J, Tyrrell L, Lu S Z, Ma Y S, Langley K, Ding T G, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312–314
   PubMed Web of Science ®Google Scholar
• Longley Jr BJ, Metcalfe D D, Tharp M, Wang X, Tyrrell L, Lu S Z, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609–1614
   PubMed Web of Science ®Google Scholar
• Garcia-Montero A C, Jara-Acevedo M, Teodosio C, Sanchez M L, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366–2372
   PubMed Web of Science ®Google Scholar
• Buttner C, Henz B M, Welker P, Sepp N T, Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998; 111: 1227–1231
   PubMed Web of Science ®Google Scholar
• Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737–746
   PubMed Web of Science ®Google Scholar
• Pignon J M, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997; 96: 374–376
   PubMed Web of Science ®Google Scholar
• Pullarkat V A, Bueso-Ramos C, Lai R, Kroft S, Wilson C S, Pullarkat S T, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003; 73: 12–17
   PubMed Web of Science ®Google Scholar
• Horny H P, Sotlar K, Sperr W R, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604–608
   PubMed Web of Science ®Google Scholar
• Nagai S, Ichikawa M, Takahashi T, Sato H, Yokota H, Oshima K, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 2007; 35: 1747–1752
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007; 31: 261–265
   PubMed Web of Science ®Google Scholar
• Butterfield J H, Weiler D, Dewald G, Gleich G J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345–355
   PubMed Web of Science ®Google Scholar
• Akin C BK, D'Ambrosio C, Kirshenbaum A S, Ma Y, Longley B J, Metcalfe D D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686–692
   PubMed Web of Science ®Google Scholar
• Noack F, Sotlar K, Notter M, Thiel E, Valent P, Horny H P. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma 2004; 45: 2295–2302
   PubMed Web of Science ®Google Scholar
• Ma Y, Cunningham M E, Wang X, Ghosh I, Regan L, Longley B J. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999; 274: 13399–13402
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y. Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol 1995; 107: 54–56
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355–365
   PubMed Web of Science ®Google Scholar
• Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990; 18: 5322
   PubMed Web of Science ®Google Scholar
• Blechman J M, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, et al. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 1995; 80: 103–113
   PubMed Web of Science ®Google Scholar
• Reith A D, Ellis C, Lyman S D, Anderson D M, Williams D E, Bernstein A, et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. Embo J 1991; 10: 2451–2459
   PubMed Web of Science ®Google Scholar
• Crosier P S, Ricciardi S T, Hall L R, Vitas M R, Clark S C, Crosier K E. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 1993; 82: 1151–1158
   PubMed Web of Science ®Google Scholar
• Hayashi S, Kunisada T, Ogawa M, Yamaguchi K, Nishikawa S. Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res 1991; 19: 1267–1271
   PubMed Web of Science ®Google Scholar
• Molderings G J, Kolck U W, Scheurlen C, Bruss M, Homann J, Von Kugelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007; 42: 1045–1053
   PubMed Web of Science ®Google Scholar
• Piao X, Curtis J E, Minkin S, Minden M D, Bernstein A. Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 1994; 83: 476–481
   PubMed Web of Science ®Google Scholar
• Akin C, Fumo G, Yavuz A S, Lipsky P E, Neckers L, Metcalfe D D. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222–3225
   PubMed Web of Science ®Google Scholar
• Lasota J, Kopczynski J, Majidi M, Miettinen M, Sarlomo-Rikala M. Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript. Am J Pathol 2002; 161: 739–741
   PubMed Web of Science ®Google Scholar
• Escribano L, Garca-Montero A, Nunez-Lopez R, Lopez-Jimenez J, Almeida J, Prados A, et al. Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. J Allergy Clin Immunol 2004; 114: 28–33
   PubMed Web of Science ®Google Scholar